Acknowledgements
The authors wish to thank R Knall for providing experimental data on OT-1 T cells, P Paszkiewicz and C Stemberger for carefully reading the manuscript.
Financial & competing interests disclosure
The authors were supported by SFB TR36 (TP-B10/13). Streptamer technology is covered by US Patent 4,776,562 (patent holder Dirk H. Busch and Hermann Wagner). Streptamer products are commercialized by IBA GmbH (Göttingen) and Stage Cell Therapeutics (Göttingen). The authors have no other relevant affiliations or other financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.